Sales & Marketing Bluesky offers an opportunity pharma should not ignore As X becomes a battleground for increasingly polarised debate, its lesser-known (but strikingly similar) cousin Bluesky is rapidly gaining traction.
Oncology Inside ESMO 2024: Treatments, trials, and top HCPs on social... Discover the latest treatments, clinical trials, and top healthcare professionals sharing insights on social media from the ESMO 2024 conference.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.